ICON Launches Medical Device & Diagnostics Research Group
Dublin, Ireland, 9th March, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of a new Medical Device & Diagnostics Research group focused on the unique requirements of the medical device and diagnostics industry.
The new group combines the medical and regulatory device and diagnostic expertise of Aptiv Solutions, which ICON acquired in 2014, with ICON’s global clinical development and commercialisations solutions. Device and diagnostic manufacturers can now benefit from an expanded suite of services that support the full product lifecycle, including global clinical trial execution, health economics and pricing and market access solutions.
“The device and diagnostic development model can differ significantly from that of pharmaceutical companies, both in complexity and time to market,” commented Elizabeth Thiele, President, ICON Commercialisation & Outcomes. “Operating under specific medical device SOPs and ISO certification, our new Medical Device & Diagnostics Research team has the expertise and flexibility to help manufacturers take time and cost from their development programmes and maximise the value of their products.”
ICON’s Medical Device & Diagnostics Research group will be led by Vicki Anastasi, Vice President, Medical Device & Diagnostic Research, who has over 20 years of medical device and diagnostics experience. The group is comprised of a team of dedicated project managers and clinical operations professionals as well as regulatory and strategic consultants.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
